Andrea D. Branch, A Good Antisense Molecule Is Hard To Find, TIBS—23 1998, pp. 45-50.* |
Stanley T. Crooke, Antisense Research And Application, pp. 1-50.* |
Karen Pihl-Carey, Isis To Restructure Crohn's Disease Drug Fails In Phase III, The Daily Biotechnology Newspaper, vol. 10, No. 239, pp. 1-2.* |
Giorgio Palu′ et al., In Pursuit Of New Developments For Gene Therapy Of Human Diseases, Journal Of Biotechnology, 68 (1999), pp. 1-13.* |
Natalie Milner et al., Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays, Nature Biotechnology, vol. 15, Jun. 1997, pp. 537-541.* |
Bourquin et al., A serine/arginine-rich nuclear matrix cyclophilin interacts with the C- terminal domain of RNA polymerase II, Nucleic Acids Res., 1997, 25:2055-2061. |
Corden et al., A CTD function linking transcription to splicing, Trends Biochem. Sci., 1997, 22:413-416. |
Mortillaro et al., Matrin CYP, an SR-rich cyclophilin that associates with the nuclear matrix and splicing factors, J. Biol. Chem., 1998, 273:8183-8192. |
Nestel et al., RS cyclophilins: identification of an NK-TR1-related cyclophilin, Gene, 1996, 180:151-155. |
Steinmetz, Pre-mRNA processing and the CTD of RNA polymerase II: the tail that wags the dog?, Cell, 1997, 89:491-494. |